证券之星消息，截至2026年1月30日收盘，开立医疗(300633)报收于27.75元，上涨0.65%，换手率 0.87%，成交量3.76万手，成交额1.04亿元。 1月30日的资金流向数据方面，主力资金净流入297.16万元，占总成交额2.85%，游资资金净流出80.62 万元，占总成交额0.77%，散户资金净流出216.53万元，占总成交额2.08%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过 ...

在消化内镜领域，复杂术式并不难学，但要在本地临床中长期、稳定开展，难度远高于预期。短期培训难以覆盖反复操作、团队磨合等关键环节，能力能否持续沉 淀，成为实践中的现实问题。 2025 年，开立医疗围绕"一带一路"倡议，在全国多地持续推进 "一带一路'友谊'国际消化内镜学院"项目 。 通过系统化课程设计，并结合新一代智慧内镜平台 iEndo 的深度参与，该项目将教学、临床与设备整合为一套可反复运行、可扩展的协作模式。 这不仅是一轮密集而持续的年度行动，也逐渐呈现出一套清晰的赋能体系。 五地联动，一年多场：一张持续展开的国际教学版图 01 2025年，开立医疗围绕国际消化内镜交流，从年初到年末，在南昌、北京、遵义、上海、西安五地接续开展"一带一路'友谊'国际消化内镜学院"系列培训活动，形 成了一条清晰的年度教学轨迹。这些活动不仅在国内多地举行，还吸引了来自葡萄牙、埃及、尼泊尔、印度、菲律宾、俄罗斯、伊朗、泰国、博茨瓦纳、巴基斯 坦、越南等 11个国家的50余名内镜医生 参与。 当这些分布在不同时间、不同地点的培训活动被放在同一条时间轴上观察时，我们可以看到： 一套面向国际医生、围绕复杂消化内镜术式展开的系统化教学网 ...

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 证券之星消息，截至2026年1月27日收盘，开立医疗(300633)报收于28.3元，下跌1.97%，换手率 0.81%，成交量3.5万手，成交额9904.12万元。 1月27日的资金流向数据方面，主力资金净流入358.38万元，占总成交额3.62%，游资资金净流出127.24 万元，占总成交额1.28%，散户资金净流出231.13万元，占总成交额2.33%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有8家机构给出 ...

证券之星消息，截至2026年1月26日收盘，开立医疗(300633)报收于28.87元，下跌0.62%，换手率 1.48%，成交量6.42万手，成交额1.83亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1月26日的资金流向数据方面，主力资金净流入143.99万元，占总成交额0.79%，游资资金净流出234.54 万元，占总成交额1.28%，散户资金净流入90.55万元，占总成交额0.49%。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗 ...

Investment Rating - The report indicates a positive outlook for the medical equipment industry, with an expected year-on-year growth of 25% for the year 2025 [22]. Core Insights - The medical equipment industry is experiencing a slight decline in December data year-on-year, attributed to a high base effect from the previous year. However, there is a significant month-on-month increase of 38% due to accelerated budget spending at year-end [3]. - The report highlights that the current round of medical equipment upgrades is nearing its end, with expectations for a new round of equipment replacement in 2025, which is projected to be no less than the previous round [4]. - The report emphasizes the importance of government policies, including the issuance of long-term special bonds to support large-scale equipment upgrades and consumer replacement programs [15]. Summary by Relevant Sections Medical Imaging - December figures for medical imaging reached 9.8 billion yuan, a decrease of 11%, while the forecast for 2025 is 69.3 billion yuan, reflecting a growth of 37% [5]. Life Information and Support - In December, life information and support equipment generated 2.6 billion yuan, an increase of 8%, with a projected total of 16.7 billion yuan for 2025, marking a 28% growth [5]. Endoscopes - Soft endoscopes reported 1.1 billion yuan in December, down 9%, while hard endoscopes reached 1.2 billion yuan, down 7%. The 2025 projections for both are 7.8 billion yuan for soft endoscopes (+12%) and 7.8 billion yuan for hard endoscopes (+3%) [5]. Radiation Therapy - December figures for radiation therapy stood at 1.6 billion yuan, a slight increase of 1%, with a forecast of 9.6 billion yuan for 2025, indicating a growth of 32% [48]. Surgical Robots - Surgical robots saw a significant decline in December, with figures at 600 million yuan, down 24%, but are expected to reach 5.2 billion yuan in 2025, reflecting a robust growth of 54% [51]. Key Companies - Major companies in the sector include Mindray, which reported 1.9 billion yuan in December (+20%) and is projected to reach 11.2 billion yuan in 2025 (+35%), and United Imaging, with December figures of 2.2 billion yuan (0% change) and a forecast of 12.6 billion yuan (+37%) for 2025 [55][58].

证券之星消息，截至2026年1月22日收盘，开立医疗(300633)报收于28.11元，上涨0.14%，换手率 0.7%，成交量3.01万手，成交额8489.49万元。 1月22日的资金流向数据方面，主力资金净流入333.43万元，占总成交额3.93%，游资资金净流入86.37 万元，占总成交额1.02%，散户资金净流出419.8万元，占总成交额4.94%。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为 ...

证券之星消息，截至2026年1月21日收盘，开立医疗(300633)报收于28.07元，上涨0.14%，换手率 0.98%，成交量4.26万手，成交额1.2亿元。 1月21日的资金流向数据方面，主力资金净流入189.85万元，占总成交额1.58%，游资资金净流入819.74 万元，占总成交额6.82%，散户资金净流出1009.59万元，占总成交额8.4%。 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（30063 ...

Core Viewpoint - The company is committed to a "device + AI" strategy and has not yet ventured into the brain-computer interface field [1] Group 1 - The company has stated its focus on exploring AI in the medical equipment sector [1] - Detailed information regarding the company's activities in the AI medical equipment field can be found in its annual report disclosed on the Giant Tide Information Network [1]

Core Viewpoint - The stock of Kaili Medical (300633) has shown a decline in price and significant changes in financial performance, indicating potential investment considerations and market reactions [1][2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of January 19, 2026, the stock closed at 28.5 yuan, down 1.08%, with a turnover rate of 0.8% [1]. - The trading volume was 34,400 hands, with a total transaction amount of 99.12 million yuan [1]. - On January 19, the net outflow of main funds was 5.936 million yuan, accounting for 5.99% of the total transaction amount [1]. - Retail investors saw a net inflow of 4.33 million yuan, representing 4.37% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Kaili Medical, with 8 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].

1月16日，开立医疗跌3.13%，成交额1.54亿元。两融数据显示，当日开立医疗获融资买入额929.75万 元，融资偿还1872.30万元，融资净买入-942.55万元。截至1月16日，开立医疗融资融券余额合计1.38亿 元。 融资方面，开立医疗当日融资买入929.75万元。当前融资余额1.38亿元，占流通市值的1.11%，融资余 额低于近一年50%分位水平，处于较低位。 截至9月30日，开立医疗股东户数1.61万，较上期增加12.75%；人均流通股26824股，较上期减少 11.31%。2025年1月-9月，开立医疗实现营业收入14.59亿元，同比增长4.37%；归母净利润3351.11万 元，同比减少69.25%。 分红方面，开立医疗A股上市后累计派现3.81亿元。近三年，累计派现2.58亿元。 融券方面，开立医疗1月16日融券偿还500.00股，融券卖出500.00股，按当日收盘价计算，卖出金额1.44 万元；融券余量5100.00股，融券余额14.69万元，低于近一年10%分位水平，处于低位。 资料显示，深圳开立生物医疗科技股份有限公司位于广东省深圳市光明区光电北路368号开立医疗大 厦，成立日期20 ...